Athersys (NASDAQ:ATHX) was downgraded by equities researchers at ValuEngine from a “hold” rating to a “sell” rating in a report released on Tuesday, December 5th.
ATHX has been the topic of several other research reports. Maxim Group restated a “buy” rating and set a $12.00 price objective on shares of Athersys in a report on Friday, September 1st. Zacks Investment Research downgraded shares of Athersys from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $7.17.
Athersys (NASDAQ:ATHX) traded down $0.06 on Tuesday, reaching $1.81. 453,247 shares of the company’s stock traded hands, compared to its average volume of 681,364. Athersys has a 1 year low of $1.02 and a 1 year high of $2.63. The firm has a market capitalization of $221.66, a P/E ratio of -6.46 and a beta of -0.38.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of America Corp DE grew its stake in shares of Athersys by 17.2% in the 1st quarter. Bank of America Corp DE now owns 61,580 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 9,019 shares in the last quarter. SG Americas Securities LLC grew its stake in shares of Athersys by 329.7% in the 2nd quarter. SG Americas Securities LLC now owns 73,434 shares of the biopharmaceutical company’s stock worth $111,000 after acquiring an additional 56,345 shares in the last quarter. State of Wisconsin Investment Board bought a new stake in shares of Athersys in the 2nd quarter worth $113,000. Blair William & Co. IL grew its stake in shares of Athersys by 708.0% in the 2nd quarter. Blair William & Co. IL now owns 80,804 shares of the biopharmaceutical company’s stock worth $122,000 after acquiring an additional 70,804 shares in the last quarter. Finally, Thompson Davis & CO. Inc. grew its stake in shares of Athersys by 743.9% in the 3rd quarter. Thompson Davis & CO. Inc. now owns 64,303 shares of the biopharmaceutical company’s stock worth $132,000 after acquiring an additional 56,683 shares in the last quarter. Hedge funds and other institutional investors own 21.01% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Athersys (ATHX) Downgraded by ValuEngine to “Sell”” was originally posted by Week Herald and is the property of of Week Herald. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://weekherald.com/2017/12/30/athersys-athx-stock-rating-lowered-by-valuengine.html.
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.